NEWS

  • IMAGO BIOSCIENCES TO EXPAND CLINICAL TRIAL OF IMG-7829 FOR MF PATIENTS

    Presented at the 24th Congress of the European Hematology Association (EHA), Imago BioSciences, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 1/2a clinical trial of a lysine-specific demethylase (LSD1) inhibitor, IMG-7289. Imago decided to expand the study into a Phase 2b trial and is evaluating clinical investigations in additional myeloid diseases. “IMG-7289 has… Read More »IMAGO BIOSCIENCES TO EXPAND CLINICAL TRIAL OF IMG-7829 FOR MF PATIENTS

    READ MORE

    1 35 36 37
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?